Biomarkers of Synaptic Damage in Multiple Sclerosis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Biomarkers of Synaptic Damage in Multiple Sclerosis — Stella

Recruiting

Back to Multiple Sclerosis trials

Trial locations(1 site)

Italy

IRCCS Neuromed, Pozzilli, Isernia

Key details

Sponsor

Neuromed IRCCS

Collaborators

IRCCS Multimedica

Enrollment target

~300 participants

Started

November 2017

Primary completion

September 2026

Age range

18 Years – 65 Years

Last updated October 2022

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov